3Suppliers
6Customers
2Debt Items
20Related Chains

Ocular Therapeutix, Inc. Suppliers

TickerNameConfidenceEvidence
CELG-RI CELG-RI 72% uman use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the …
CELG-RI CELG-RI 72% Reciprocal relationship from CELG-RI graph: Reciprocal relationship from OCUL graph: uman use. European Union member states may approve a specific price for a drug product or it may instead adopt a s…
IRD Opus Genetics, Inc. 72% Reciprocal relationship from IRD graph: line products, our business will be materially harmed. • Others may discover, develop, or commercialize products similar to those in our pipeline before or mor…

Ocular Therapeutix, Inc. Customers

TickerNameConfidenceEvidence
CUSTOMER-1 CUSTOMER-1 90% Three specialty distributor customers accounted for the following percentages of the Company’s total revenue: Customer 1 38 % 39 %
CUSTOMER-2 CUSTOMER-2 90% Three specialty distributor customers accounted for the following percentages of the Company’s total revenue: Customer 2 28 24
CUSTOMER-3 CUSTOMER-3 90% Three specialty distributor customers accounted for the following percentages of the Company’s total revenue: Customer 3 7 8
CELG-RI CELG-RI 72% uman use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the …
CELG-RI CELG-RI 72% Reciprocal relationship from CELG-RI graph: Reciprocal relationship from OCUL graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from OCUL graph: uman use. European Union memb…
IRD Opus Genetics, Inc. 72% Reciprocal relationship from IRD graph: Reciprocal relationship from OCUL graph: Reciprocal relationship from IRD graph: Reciprocal relationship from OCUL graph: Reciprocal relationship from IRD grap…

Ocular Therapeutix, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
OCUL-DEBT-11486 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.
OCUL-DEBT Debt stack $79.5M 90% Market cache reports total debt of $79.5M.

Ocular Therapeutix, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Ocular Therapeutix, Inc..

Ocular Therapeutix, Inc. Ownership

HolderNameConfidenceEvidence
OCUL-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 272 tracked holders.

Ocular Therapeutix, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ANIP ANI Pharmaceuticals, Inc. 100.00 2
CELG-RI BRISTOL MYERS SQUIBB CO 100.00 1 ['customer', 'supplier']
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
FDMT 4D Molecular Therapeutics, Inc. 100.00 2
OTLK Outlook Therapeutics, Inc. 100.00 2
IRD Opus Genetics, Inc. 100.00 1 ['customer', 'supplier']
LLY Eli Lilly and Company 100.00 2
NVSEF Novartis AG 100.00 2
PPBT Purple Biotech Ltd 50.00 2
GNLX Genelux Corporation 50.00 2
TRVI Trevi Therapeutics, Inc. 50.00 2
INAB IN8bio, Inc. 50.00 2
HOWL Werewolf Therapeutics, Inc. 50.00 2
ZBIO Zenas BioPharma, Inc. 50.00 2
ORANY ORANGE 50.00 2
VYGR Voyager Therapeutics, Inc. 50.00 2
MYGN Myriad Genetics, Inc. 50.00 2
SMMT Summit Therapeutics Inc. 50.00 2
RNTX Rein Therapeutics Inc. 50.00 2
XLO Xilio Therapeutics, Inc. 50.00 2